Loriot Yohann, Rouprêt Morgan
Département de médecine oncologique et INSERM U981, Gustave-Roussy, Cancer Campus, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Sorbonne Université, GRC n° 5, PRÉDICTIVE ONCO-URO, AP-HP, Urologie, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
Bull Cancer. 2020 Jun;107(5S):S49-S55. doi: 10.1016/S0007-4551(20)30278-2.
Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.
在日常临床实践中，局部和全身免疫疗法用于膀胱癌的治疗。卡介苗（BCG）已用于非肌层浸润性膀胱癌（NMIBC）患者近40年。尽管其疗效显著，但仍有近30%的患者出现疾病进展。鉴于免疫检查点抑制剂在转移性疾病中的抗肿瘤活性，目前正在NMIBC中对这些疗法进行研究。派姆单抗现已获得美国食品药品监督管理局（FDA）批准，用于治疗卡介苗无反应、高危、伴有原位癌且有或无乳头状肿瘤、不适合或未选择接受膀胱切除术的NMIBC患者。目前正在进行多项3期试验，以研究PD（L）1抑制剂联合卡介苗的疗效，如法国的ALBAN研究。
